Zura Bio updates corporate investor presentation
Zura Bio Limited furnished an updated corporate presentation dated July 1, 2026 for use at upcoming conferences and investor meetings.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Zura Bio Limited furnished an updated corporate presentation dated July 1, 2026 for use at upcoming conferences and investor meetings. The presentation is provided as Exhibit 99.1 and is also available in the News & Events section of the company’s investor website.
The information is furnished under Item 7.01 of Form 8-K and is not deemed filed for purposes of Section 18 of the Exchange Act or Sections 11 and 12(a)(2) of the Securities Act, nor incorporated by reference into other SEC filings unless specifically referenced.
8-K Event Classification
Key Terms
Emerging growth company regulatory
corporate presentation financial
Section 18 of the Securities Exchange Act of 1934 regulatory
Sections 11 and 12(a)(2) of the Securities Act of 1933 regulatory
Inline XBRL technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Zura Bio (ZURA) disclose in its latest 8-K filing?
How can investors access Zura Bio’s July 1, 2026 corporate presentation?
Is Zura Bio’s new corporate presentation considered filed with the SEC?
Will Zura Bio’s Exhibit 99.1 be incorporated into other SEC filings?
What is Zura Bio’s status as an emerging growth company in this filing?
Who signed Zura Bio’s July 1, 2026 Form 8-K and in what roles?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form
Current Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
(Address of principal
executive offices,
including zip code)
(
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name
of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
| Item 7.01. | Regulation FD Disclosure. |
On July 1, 2026, Zura Bio Limited (the “Company”) provided an updated corporate presentation that may be used in connection with upcoming presentations at conferences and investor meetings. The full text of the Company’s corporate presentation is furnished as Exhibit 99.1 hereto, and incorporated herein by reference, and may also be accessed through the “News & Events” section of the Company’s website at investors.zurabio.com.
The information furnished under this Item 7.01 (including Exhibit 99.1), shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such a filing.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit No. | Description |
| 99.1 | Corporate Presentation, dated July 1, 2026 |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ZURA BIO LIMITED | ||
| Date: July 1, 2026 | By: | /s/ Kim Davis |
| Kim Davis | ||
| Chief Operating Officer, Chief Legal Officer and Corporate Secretary | ||
Exhibit 99.1
| Corporate Overview July 2026 Nasdaq Ticker: ZURA |
| ©2026 Zura Bio Ltd. 2 Forward-looking statements disclaimer This presentation contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believe,” “predict,” “potential,” “continue,” “strategy,” “future,” “opportunity,” “would,” “seem,” “seek,” “outlook,” “goal,” “mission,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations, estimates, and assumptions and, as a result, are subject to risks and uncertainties that could cause actual results to differ materially from the expected results. These statements are based on various assumptions, whether or not identified in this presentation. These forward-looking statements may include, without limitation: Zura Bio’s clinical development plans; the design, initiation, conduct, enrollment and timing of its clinical trials; expectations regarding the timing of key milestones and anticipated data readouts; expectations regarding clinical programs, including the safety, efficacy, and therapeutic potential of Zura Bio’s product candidates; expectations regarding the commercial potential of Zura Bio’s product candidates; expectations regarding data readouts from third parties; expectations regarding market opportunities, including estimated total addressable markets, competitive landscape, addressable patient populations, or potential clinical differentiation; Zura Bio’s cash resources and projected cash runway; Zura Bio’s business strategies and objectives; and any other statements that are not historical facts. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by an investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events are difficult or impossible to predict and could differ materially from those expressed or implied in such forward-looking statements, as a result of these risks and uncertainties, which include, but are not limited to: Zura Bio’s expectations regarding its product candidates and their related benefits, and Zura Bio’s beliefs regarding competing product candidates or approved products, may not be achieved; Zura Bio's vision and strategy may not be successful; the timing of key events and initiation of Zura Bio's studies, and release of clinical data may take longer than anticipated or may not be achieved at all; the potential general acceptability and maintenance of Zura Bio's product candidates by regulatory authorities, payors, physicians, and patients may not be achieved; Zura Bio's ability to attract and retain key personnel; Zura Bio's expectations with respect to its future operating expenses, capital requirements and needs for additional financing may not be achieved; Zura Bio has not completed any clinical trials, and has no products approved for commercial sale; Zura Bio has incurred significant losses since inception, and expects to incur significant losses for the foreseeable future and may not be able to achieve or sustain profitability in the future; Zura Bio requires substantial additional capital to finance its operations, and if it is unable to raise such capital when needed or on acceptable terms, Zura Bio may be forced to delay, reduce, and/or eliminate one or more of its development programs or future commercialization efforts; Zura Bio may be unable to renew existing contracts, or enter into new contracts or may experience disputes or other challenges with respect to our vendors or other third parties; Zura Bio relies on third-party contract development manufacturing organizations for the manufacture of clinical materials; Zura Bio relies on contract research organizations, clinical trial sites, and other third parties to conduct its preclinical studies and clinical trials; Zura Bio may be unable to obtain regulatory approval for its product candidates, and there may be related restrictions or limitations of any approved products; Zura Bio may be unable to successfully respond to general economic and geopolitical conditions; Zura Bio may be unable to effectively achieve or manage growth; Zura Bio faces competitive pressures from other companies worldwide; Zura Bio may be unable to adequately protect its intellectual property rights; and other factors set forth in documents filed, or to be filed by Zura Bio, with the Securities and Exchange Commission (SEC), including the risks and uncertainties described in the “Risk Factors” section of Zura Bio’s Annual Report on Form 10-K for the year ended December 31, 2025, and other filings with the SEC. Zura Bio cautions that the foregoing list of factors is not exclusive or exhaustive and not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Zura Bio does not undertake or accept any obligation to update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by law. Zura gives no assurance can be given that the expectations expressed herein will be achieved orthat deviations from such expectations will not be material. This presentation discusses product candidates that are under clinical investigation and have not been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety, efficacy, or likelihood of regulatory approval of these product candidates for the uses under investigation. Comparisons across clinical trials or product candidates should be interpreted with caution, as differences in study design, inclusion/exclusion criteria, patient populations, endpoints, dosing regimens, and other variables may limit interpretability. Statements in this presentation regarding clinical trials involving product candidates originating from third parties (including Eli Lilly, Pfizer and Novartis) have not been reviewed, verified, or endorsed by such parties. |
| ©2026 Zura Bio Ltd. Zura Bio: advancing a differentiated approach for complex immune disorders Our lead program, tibulizumab, is the first and currently only in-class bispecific antibody inhibiting both the IL-17 and BAFF pathways ▪ Fusion of components from tabalumab, a BAFF-binding antibody, and an IL-17–binding single-chain variable fragment derived from ixekizumab (marketed as Taltz®, ~$3.6B in global 2025 sales, as reported) ▪ Potent engagement of targets and low immunogenicity observed in completed Phase 1 studies Tibulizumab has been rationally designed to address complex autoimmune diseases not fully addressed by single-pathway therapies ▪ Dual-pathway inhibition offers the potential to overcome efficacy ceilings observed with single-pathway inhibition ▪ Potential to modulate both B-cell– and T-cell–driven pathobiology Initial clinical focus on hidradenitis suppurativa (HS) and systemic sclerosis (SSc), each characterized by complex immune pathobiology involving both B- and T-cell activation ▪ HS: potential to be the best-in-class treatment by inhibiting two pathways already independently validated ▪ SSc: potential to be first-in-disease treatment able to treat both skin and lung manifestations, where both IL-17 and BAFF have been implicated ▪ Zura plans to initiate a Phase 2 study for tibulizumab in a third immune-mediated indication by year end 2026 Zura Bio is financed beyond key near-term value inflection points ▪ Topline data expected from HS and SSc phase 2 studies in Q4 2026 and 1H 2027, respectively ▪ ~$225.6M in cash and cash equivalents as of March 31, 2026 ▪ Public offering in February 2026 expected to enable the Company to fund planned operations through at least the end of 2028 ▪ As a result of recent February 2026 public offering, ~124M shares outstanding (as-converted)* 3 Nasdaq: ZURA (*) Shares outstanding as of March 31, 2026; includes 21.2 million shares issued as part of February 2026 financing and ~29.3 million shares issuable upon conversion of outstanding pre-funded warrants to purchase Class A ordinary shares. This figure does not reflect potential dilution from outstanding stock options or unvested RSUs. Sources: Zura Bio Ltd., public filings and disclosures; Evaluate Pharma; publicly available information on ixekizumab (Taltz®) and tabalumab. Acronyms: BAFF, B-cell activating factor; HS, hidradenitis suppurativa; IL-17, interleukin-17; scFv, single-chain variable fragment; SSc, systemic sclerosis. |
| ©2026 Zura Bio Ltd. 4 Executive Team and Board of Directors Amit Munshi Chairman Sandeep Kulkarni, MD Co-Founder, CEO & Director Dan Becker, MD, PhD Director Mark Eisner, MD, MPH Director Jennifer Jarrett Director Ajay Nirula, MD, PhD Director Steve Schoch Director Parvinder Thiara Director Board of Directors Nasdaq: ZURA Executive Team Kim Davis, JD Chief Operating Officer, Chief Legal Officer and Corporate Secretary Gary Whale, PhD Chief Technology Officer Kiran Nistala, MBBS, PhD Chief Medical Officer and Head of Development Sandeep Kulkarni, MD Co-Founder, Chief Executive Officer and Director Muzammil Mustufa Chief Business Officer |
| Sources: ClinicalTrials.gov ID NCT06993610; ClinicalTrials.gov ID NCT06843239. ©2026 Zura Bio Ltd. Acronyms: HS, hidradenitis suppurativa; SSc, systemic sclerosis. 5 Tibulizumab advancing clinically in high unmet need multi-pathway immune-mediated diseases Nasdaq: ZURA A Phase 2 trial in adults with HS Enrollment completed; 247 participants randomized Anticipated readout: Q4 2026 Optionality for pipeline expansion into additional autoimmune indications with complex immune pathobiology A Phase 2 trial in adults with SSc On track to complete enrollment early July 2026; exceeded 80 participant enrollment target Anticipated readout: 1H 2027 Phase 2 trial in a third immune-mediated indication Initiation: By year-end 2026 |
| ©2026 Zura Bio Ltd. Limits of monotherapy in multi-pathway autoimmune disease Acronyms: HS, hidradenitis suppurativa; SSc, systemic sclerosis. 6 Nasdaq: ZURA Implication: these limitations support therapeutic approaches designed to address more than one disease-driving pathway with a single agent ▪ Autoimmune diseases, including HS and SSc, are driven by multiple, intersecting immune pathways, resulting in biological heterogeneity across patients ▪ Single-pathway biologics may deliver low or inadequate response rates in complex autoimmune diseases ▪ Even among responders, pathway redundancy and compensatory signaling can limit depth and durability of response with monotherapy |
| ©2026 Zura Bio Ltd. Tibulizumab: a single-molecule dual-pathway approach Tibulizumab is an investigational agent. Its efficacy and safety have not been established or approved by the FDA or any regulatory agency worldwide. Sources: ClinicalTrials.gov ID NCT06993610; ClinicalTrials.gov ID NCT06843239; Publicly available information on ixekizumab and tabalumab; Benschop et al., mAbs (2019), DOI: 10.1080/19420862.2019.1624463. Acronyms: Ab, antibody; BAFF, B-cell activating factor; HS, hidradenitis suppurativa; IL-17, interleukin-17; IL-17A/F, interleukin-17A/interleukin-17F heterodimer; scFv, single-chain variable fragment; SSc, systemic sclerosis. 7 Nasdaq: ZURA Addresses disease complexity: aims to target two distinct immune pathways implicated in chronic inflammation and autoimmunity Clinically grounded design: fusion of a BAFF-binding antibody (tabalumab) with the IL-17A-binding scFv from ixekizumab Single-entity advantage: enables dual-pathway modulation without multi-drug combination complexity ixekizumab Anti-IL-17 scFv IL-17A & IL-17A/F tabalumab Anti-BAFF Ab BAFF tibulizumab Tetravalent bispecific antibody designed to block BAFF and IL-17A–mediated signaling, including IL-17A/F heterodimers Inhibition of BAFF and IL-17A in one bispecific antibody |
| ©2026 Zura Bio Ltd. Phase 1/1b data support advancement of tibulizumab into Phase 2 development 8 Tibulizumab is an investigational agent. Its efficacy and safety have not been established or approved by the FDA or any regulatory agency worldwide. (*) Model-predicted median maximum percent change from baseline of free unbound BAFF and IL-17 following the last dose. Values shown reflect steady-state trough suppression. Sources: Eli Lilly and Company–conducted Phase 1/1b clinical studies; Zura Bio Ltd. internal clinical study reports (CSRs). Acronyms: ADA, anti-drug antibody; BAFF, B-cell activating factor; CFB, change from baseline; CRP, C-reactive protein; IL-17, interleukin-17; PD, pharmacodynamics; PK, pharmacokinetics; Q4W, once every 4 weeks. Nasdaq: ZURA ▪ 78 participants dosed across Phase 1/1b studies ▪ >98% median trough target engagement for both IL-17 and BAFF in peripheral blood at 300 mg Q4W ▪ Mean terminal half-life (t½): 26.9 days, supporting once-monthly dosing ▪ Pharmacodynamic activity observed, including B cell and CRP reductions ▪ Low incidence of treatment-emergent ADAs in multiple-dose cohorts ▪ Safety profile consistent with published IL-17 and BAFF pathway experience, with no new or unexpected safety signals to date Time (weeks) Free BAFF concentration %CFB Free IL-17 concentration %CFB 100 mg Q4W 300 mg Q4W 100 mg Q4W 300 mg Q4W Population prediction interval* Median free target concentration Dose-dependent and comparable BAFF and IL-17 target engagement Model-based PK/PD analysis demonstrates a clear exposure–response relationship, with comparable BAFF and IL-17 suppression and near-complete target engagement at higher doses |
| ©2026 Zura Bio Ltd. BAFF: a clinically validated immune pathway central to B cell survival 9 Sources: Vincent, F.B. et al. (2013), Cytokine & Growth Factor Reviews, DOI:10.1016/j.cytogfr.2013.04.003; Smulski, C.R. and Eibel, H. (2018), Frontiers in Immunology, DOI:10.3389/fimmu.2018.02285; Matsushita, T. et al. (2005), Arthritis & Rheumatism, DOI:10.1002/art.21526.; Sabat, R. et al. (2023), Journal of Allergy and Clinical Immunology, DOI:10.1016/j.jaci.2022.10.034. Acronyms: Ab, antibody; BAFF, B-cell activating factor; HS, hidradenitis suppurativa; IL-17, interleukin-17; IL-17A/F, interleukin-17A/interleukin-17F heterodimer; scFv, single-chain variable fragment; SSc, systemic sclerosis. Nasdaq: ZURA BAFF represents a clinically validated immune pathway addressing a fundamental driver of chronic autoimmune disease biology ▪ BAFF is a non-redundant survival factor supporting persistence and differentiation of autoreactive B cells ▪ Genetic, translational, and clinical data show that disruption of BAFF signaling leads to marked reductions in peripheral B cells ▪ Elevated BAFF levels and B cell dysregulation are reported across immune-mediated diseases, including HS and SSc ▪ BAFF inhibition targets a core B cell survival pathway distinct from IL-17–mediated inflammatory signaling ixekizumab Anti-IL-17 scFv tabalumab Anti-BAFF Ab BAFF tibulizumab Tetravalent bispecific antibody designed to block BAFF and IL-17A–mediated signaling, including IL-17A/F heterodimers |
| ©2026 Zura Bio Ltd. IL-17A: a clinically validated inflammatory pathway 10 The IL-17A-binding domain of tibulizumab is derived from ixekizumab. Sources: Gaffen, S.L. et al. (2014), Nature Reviews Immunology, DOI:10.1038/nri3707; Griffiths, C.E. et al. (2015), The Lancet, DOI:10.1016/s0140-6736(15)60125-8; Blauvelt, A. et al. (2021), Journal of the American Academy of Dermatology, DOI:10.1016/j.jaad.2020.11.022; Eli Lilly and Company, ixekizumab (Taltz®) Prescribing Information. Acronyms: Ab, antibody; BAFF, B-cell activating factor; IL-17, interleukin-17; IL-17A, interleukin-17A; IL-17A/F, interleukin-17A/interleukin-17F heterodimer; scFv, single-chain variable fragment. IL-17A represents a clinically validated inflammatory pathway in autoimmune disease, with approvals in rheumatology and dermatology Nasdaq: ZURA ▪ IL-17 is a central amplifier of inflammation across multiple immune-mediated diseases ▪ IL-17 pathway inhibition has demonstrated efficacy across multiple inflammatory indications, supported by extensive clinical experience ▪ Ixekizumab represents a well-established clinical benchmark for IL-17 pathway inhibition, blocking IL-17A and IL-17A/F signaling ixekizumab Anti-IL-17 scFv tabalumab Anti-BAFF Ab tibulizumab IL-17A & IL-17A/F Tetravalent bispecific antibody designed to block BAFF and IL-17A–mediated signaling, including IL-17A/F heterodimers |
| ©2026 Zura Bio Ltd. Ixekizumab: a high-efficacy clinical benchmark for IL-17 pathway inhibition ▪ Consistent high efficacy: Demonstrated across multiple inflammatory diseases in large Phase 3 programs* ▪ Validated IL-17 pathway inhibition: Neutralization of IL-17A and IL-17A/F produces robust clinical responses with a well-characterized safety profile ▪ Extensive clinical experience: Supported by large global clinical development programs and post-marketing datasets across dermatologic and rheumatologic indications* (*) PASI 90 values represent placebo-adjusted response rates at Week 12 from independent Phase 3 psoriasis trials. Studies were not designed for head-to-head comparison; trial designs, patient populations, dosing regimens, and placebo response rates differed. Clinical efficacy data shown are limited to psoriasis studies. Efficacy and durability may vary by indication. Sources: Griffiths, C.E. et al. (2015), The Lancet, DOI:10.1016/s0140-6736(15)60125-8; Langley, R.G. et al. (2014), New England Journal of Medicine, DOI:10.1056/nejmoa1314258; Gordon, K.B. et al. (2016), New England Journal of Medicine, DOI:10.1056/nejmoa1512711; Eli Lilly and Company and Novartis public disclosures and prescribing information. Acronyms: IL-17, interleukin-17; IL-17A, interleukin-17A; IL-17A/F, interleukin-17A/interleukin-17F heterodimer; PASI 90, Psoriasis Area and Severity Index 90% improvement; PBO, placebo; PsO, psoriasis. 11 Ixekizumab establishes a well-characterized clinical benchmark for IL-17 pathway inhibition Multiple Phase 3 programs completed High efficacy demonstrated Broad IL-17 pathway inhibition Extensive clinical and real-world experience Nasdaq: ZURA secukinumab PASI 90 at Week 12* (Phase 3 psoriasis studies) PASI 90 (%; PBO-adjusted) 0 10 20 30 40 50 60 70 80 ixekizumab UNCOVER-1 UNCOVER-2 UNCOVER-3 PsO1 PsO2 |
| ©2026 Zura Bio Ltd. 12 (*) Clinical studies have shown higher rates of mucocutaneous candidiasis with broader IL-17 pathway inhibition that includes IL-17F. Sources: Benschop, R.J. et al. (2019), mAbs, DOI:10.1080/19420862.2019.1624463; Adams, R. et al. (2020), Frontiers in Immunology, DOI:10.3389/fimmu.2020.01894. Acronyms: BAFF, B-cell activating factor; HS, hidradenitis suppurativa; IL, interleukin; IL-17A, interleukin-17A; IL-17F, interleukin-17F; IL-17A/A, interleukin-17A homodimer; IL-17A/F, interleukin-17A/interleukin-17F heterodimer; IL-17F/F, interleukin-17F homodimer; KD , dissociation constant; mAb, monoclonal antibody; pM, picomolar. Tibulizumab is the first and only in-class bispecific antibody targeting IL-17 and BAFF IL-17 pathway B-Cell–driven inflammation Agent Target description IL-17A/A (KD ) IL-17A/F (KD ) IL-17F/F* (KD ) Tibulizumab Anti-BAFF & IL-17 bispecific mAb ~14 pM ~90 pM no binding BAFF Secukinumab (Cosentyx®) Anti-IL-17A mAb ~60–90 pM ~2400 pM no binding no Bimekizumab (Bimzelx®) Anti-IL-17A/F mAb ~3.2 pM ~26 pM ~23 pM no Nasdaq: ZURA IL-17–only approaches ▪ Inhibits IL-17A signaling with varying affinity ▪ May also inhibit IL-17A/F or IL-17F to further suppress the IL-17 pathway ▪ Does not address additional disease drivers Tibulizumab (anti-IL-17 + BAFF) ▪ Inhibits key IL-17 ligands (IL-17A/A and IL-17A/F) ▪ Adds BAFF pathway inhibition (B-cell biology) ▪ Is designed to address multiple disease drivers |
| ©2026 Zura Bio Ltd. Tibulizumab targets two potentially high-value autoimmune market opportunities 13 Nasdaq: ZURA Source: Market estimates based on third-party analyses and published literature, including DRG/Clarivate, Evaluate Pharma, GlobalData, peer-reviewed epidemiology studies, and company analyses. Acronyms: TAM, total addressable market. Potential significant multi-billion-dollar market opportunities ▪ Growing biologics market supported by increasing diagnosis and utilization ▪ Chronic inflammatory disease with durable treatment demand and high unmet need ▪ Heterogeneous disease biology creates opportunity beyond single-pathway approaches Large and expanding chronic disease HIDRADENITIS SUPPURATIVA ~$8B projected by the mid-2030s ESTIMATED TAM ▪ Rare autoimmune disease with significant unmet need and limited effective treatment options ▪ Specialist-managed market with concentrated prescribing and premium pricing dynamics ▪ Multisystem inflammatory and fibrotic manifestations contribute to substantial disease burden High-value orphan autoimmune opportunity SYSTEMIC SCLEROSIS ~$4B projected by mid-2030s ESTIMATED TAM |
| ©2026 Zura Bio Ltd. A dual-pathway approach in HS tibulizumab ZB-106 Anti-BAFF + IL-17 ▪ First and currently only in-class bispecific antibody designed to target BAFF and IL-17 signaling, including IL-17A and IL-17A/F ▪ Phase 2 clinical trial (TibuSHIELD) ongoing; topline data anticipated in Q4 2026 Tibulizumab is an investigational agent. Its efficacy and safety have not been established or approved by the FDA or any other regulatory agency worldwide. |
| Nasdaq: ZURA | www.zurabio.com HS is a complex and relapsing disease ©2026 Zura Bio Ltd. The interplay of acute lesions, chronic inflammation, and complex immune drivers makes HS uniquely challenging, and highlights the opportunity for biology-driven solutions Patient experience ▪ HS affects ~1% of the population and is widely underdiagnosed ▪ Painful nodules and abscesses form in sensitive areas ▪ Lesions may progress to tunnels and scarring ▪ Acute flares coexist with chronic inflammation ▪ Delayed diagnosis and variable treatment response Underlying biology ▪ HS lesions are driven by a diverse, dynamic immune microenvironment ▪ Prominent immune signatures: Th1/Th17, neutrophils, B cells ▪ Chronic immune activity underlies persistent, relapsing disease course Sources: Moran, B. et al. (2017), Journal of Investigative Dermatology, DOI:10.1016/j.jid.2017.05.033; Banerjee, A. et al. (2017), Immunological Investigations, doi:10.1080/08820139.2016.1230867; Sabat, R. et al. (2023), Journal of Allergy and Clinical Immunology, DOI:10.1016/j.jaci.2022.10.034; Garg, A. et al. (2017), JAMA Dermatology, DOI:10.1001/jamadermatol.2017.0201; Ingram, J.R. (2020), British Journal of Dermatology, DOI:10.1111/bjd.19435; Midgette, B. et al. (2022), British Journal of Dermatology, DOI:10.1111/bjd.21798; Sabat, R. et al. (2020), Nature Reviews Disease Primers, DOI:10.1038/s41572-020-0149-1; MEDACorp key opinion leader (KOL) discussions. Acronyms: HS, hidradenitis suppurativa; Th1, T helper 1 cell; Th17, T helper 17 cell. tibulizumab | ZB-106 15 |
| ©2026 Zura Bio Ltd. A dual-pathway approach to hidradenitis suppurativa 16 Targeting immune drivers of chronic inflammation and tissue damage Disease ▪ Chronic, inflammatory skin disease with recurrent painful lesions ▪ Significant impact on quality of life and long-term morbidity Biology ▪ Heterogeneous disease driven by activation of multiple immune pathways ▪ BAFF elevation and associated B cell dysregulation observed in HS lesions ▪ IL-17A–driven inflammation implicated in dysfunction of neutrophils, macrophages, and keratinocytes Program ▪ Tibulizumab (BAFF + IL-17A bispecific antibody) ▪ Phase 2 TibuSHIELD clinical study in adults with HS; topline data expected Q4 2026 Th17 cell IL-17A IL-17A B cell tibulizumab | ZB-106 Acronyms: BAFF, B cell activating factor; HS, hidradenitis suppurativa; IL-17A, interleukin-17A; Th17, T helper 17 cells. |
| ©2026 Zura Bio Ltd. Neutrophils and B cells represent orthogonal immune drivers in HS Sources: Rumberger, B.E. et al. (2020), Inflammation Research, DOI:10.1007/s00011-020-01381-7; Sabat, R. et al. (2023), Journal of Allergy and Clinical Immunology, doi:10.1016/j.jaci.2022.10.034; Macchiarella, G. et al. (2023), Journal of Investigative Dermatology, DOI:10.1016/j.jid.2022.08.051; Gudjonsson, J.E. et al. (2020), JCI Insight, doi:10.1172/jci.insight.139930; Rastrick, J. et al. (2024), British Journal of Dermatology, DOI:10.1093/bjd/ljae442. Acronyms: BAFF, B-cell activating factor; B cell, B lymphocyte; HS, hidradenitis suppurativa; IL-17, interleukin-17; IL-17A, interleukin-17A; NETosis, neutrophil extracellular trap formation; T cell, T lymphocyte; TLS, tertiary lymphoid structure. 17 IL-17 and BAFF act through distinct pathways that drive neutrophil- and B cell–mediated immune pathology in HS Neutrophils: ▪ Abundant in HS lesions and sinus tracts ▪ Amplify acute inflammatory flares and tissue damage ▪ Driven in part by IL-17A–mediated recruitment and activation B cells: ▪ Activated and persistent in HS lesions ▪ Contribute to chronic immune activation ▪ Supported by BAFF-mediated survival and pro-inflammatory functions tibulizumab | ZB-106 Neutrophils and B cells are rare in healthy skin but infiltrate HS lesions |
| ©2026 Zura Bio Ltd. IL-17A– and B cell–associated pathways contribute to inflammation in HS Sources: Novartis, AAD Annual Meeting 2024; ClinicalTrials.gov ID NCT03827798; Sabat, R. et al. (2023), Journal of Allergy and Clinical Immunology, DOI:10.1016/j.jaci.2022.10.034; Macchiarella, G. et al. (2023), Journal of Investigative Dermatology, DOI:10.1016/j.jid.2022.08.051. Acronyms: BAFF, B cell activating factor; BAFF-R, B cell activating factor receptor; BTK, Bruton’s tyrosine kinase; HS, hidradenitis suppurativa; IL-17, interleukin-17; IL-17A, interleukin-17A. 18 HS is characterized by IL-17A–mediated inflammation, with emerging clinical evidence supporting B cell– pathways, underscoring the approach for multi-pathway strategies ▪ B cells and plasma cells infiltrate acute and chronic HS lesions and contribute to persistent immune activation ▪ BAFF expression aligns with B-cell and plasma-cell signatures in human HS tissue ▪ Elevated BAFF provides a biological link between B-cell accumulation and chronic immune persistence ▪ Clinical activity observed with multiple B cell–targeted approaches in HS, including BTK inhibition (remibrutinib) and BAFF-R inhibition (ianalumab) B cell / BAFF-associated biology Emerging clinical evidence ▪ Elevated IL-17 pathway activity observed in HS lesions ▪ Amplifies macrophage and neutrophil-driven inflammation and keratinocyte activation ▪ Clinical efficacy demonstrated with IL-17 pathway inhibitors IL-17A biology Clinically validated tibulizumab | ZB-106 |
| ©2026 Zura Bio Ltd. Increasing clinical evidence for B cell–related pathways in hidradenitis suppurativa* 19 tibulizumab | ZB-106 (*) Data derived from a randomized, placebo-controlled, multi-arm hidradenitis suppurativa platform study (ClinicalTrials.gov Identifier: NCT03827798). Reported results are based on information posted on ClinicalTrials.gov (as of 09-Jan-2026) and are subject to sponsor quality review and potential update. Results are descriptive and not powered for formal cross-arm comparisons. (**) sHiSCR50: ≥50% reduction in abscess and inflammatory nodule count, with no increase in abscesses or draining fistulas, assessed using a simplified lesion-count methodology. Sources: Novartis, AAD Annual Meeting 2024; ClinicalTrials.gov ID: NCT03827798. Acronyms: BAFF-R, B-cell activating factor receptor; BTK, Bruton’s tyrosine kinase; CD40, cluster of differentiation 40; HS, hidradenitis suppurativa; IL-1β, interleukin-1 beta; IL-18, interleukin-18; LPA1, lysophosphatidic acid receptor 1; sHiSCR50, Simplified Hidradenitis Suppurativa Clinical Response (50%). 72.7% 48.5% 58.6% 51.6% 46.9% 32.0% 36.0% remibrutinib (LOU064) BTKi 25 mg remibrutinib (LOU064) BTKi 100 mg iscalimab (CFZ533) anti-CD-40 ianalumab (VAY736) BAFF-R MAS825 IL-1β / IL-18 LYS006 LPA1 Pooled placebo (contemporaneous cohorts) Observed sHiSCR50** Responders at Week 16 by Treatment Arm (Observed response rates; non-responder imputation applied) Observations: ▪ Data show that B-cell–associated pathways (BTK, BAFF-R, CD40) demonstrate numerically higher sHiSCR50 response rates than pooled placebo in this HS platform study. ▪ BAFF-R inhibition (ianalumab) shows numerically meaningful observed activity, supporting a potential role for B-cell survival pathways in HS. ▪ IL-1β / IL-18 inhibition (MAS825) shows more modest observed activity with limited separation from pooled placebo. |
| ©2026 Zura Bio Ltd. HS landscape: multiple approved and late-stage therapies highlight ongoing need for differentiation 20 tibulizumab | ZB-106 Company Asset Tibulizumab (ZB-106) Adalimumab (Humira®) Secukinumab (Cosentyx®) Bimekizumab (Bimzelx®) Sonelokimab Remibrutinib Brivekimig (SAR444245) AVTX-009 Lutikizumab (ABT-981) Zasocitinib (TAK-279) Mechanism of Action Anti-BAFF and IL-17 bispecific mAb Anti-TNFα mAb Anti-IL-17A mAb Anti-IL-17A /F mAb Anti-IL-17A/F Nanobody Covalent BTK inhibitor TNFα / OX40L bispecific mAb Anti-IL-1β mAb IL-1α / IL-1β mAb TYK2 inhibitor Stage of Development Phase 2 Approved Approved Approved Phase 3 Phase 3 Phase 2 Phase 2 Phase 3 Phase 2 Route of Administration SC SC SC SC SC PO SC SC SC PO Dosing Frequency Q4W (studied) Q2W–Q4W Q4W Q2W → Q4W Q2W / Q4W (studied) QD Q4W (studied) Q2W–Q4W QW–Q2W QD Note: Approved and development status reflect HS or broader inflammatory indications as publicly reported; dosing regimens shown represent studied or labeled schedules and may vary by program. Table is descriptive and not intended to imply direct comparison between products. Sources: Company public disclosures, prescribing information, conference presentations, and ClinicalTrials.gov. Acronyms: BAFF, B cell activating factor; BTK, Bruton’s tyrosine kinase; HS, hidradenitis suppurativa; IL-1α, interleukin-1 alpha; IL-1β, interleukin-1 beta; IL-17, interleukin-17; IL-17A, interleukin-17A; IL-17A/F, interleukin-17A/interleukin-17F heterodimer; IV, intravenous; mAb, monoclonal antibody; OX40L, OX40 ligand; PO, oral administration; QD, once daily; QW, once weekly; Q2W, once every two weeks; Q4W, once every four weeks; SC, subcutaneous; TNFα, tumor necrosis factor alpha; TYK2, tyrosine kinase 2. |
| ©2026 Zura Bio Ltd. 21 (*) Includes secondary and exploratory endpoints Acronyms: AN, abscess and inflammatory nodule; DLQI, Dermatology Life Quality Index; HiSCR50, Hidradenitis Suppurativa Clinical Response ≥50%; HiSCR75, Hidradenitis Suppurativa Clinical Response ≥75%; HS, hidradenitis suppurativa; IHS4, International Hidradenitis Suppurativa Severity Score System; NRS, Numeric Rating Scale; OLE, open-label extension; PK, pharmacokinetics; PD, pharmacodynamics; SC, subcutaneous; TNF-α, tumor necrosis factor alpha. tibulizumab | ZB-106 KEY INCLUSION CRITERIA PLANNED EFFICACY ENDPOINTS PRIMARY ENDPOINT ▪ Percent change from baseline in AN count at Week 16 ADDITIONAL ENDPOINTS* ▪ HiSCR50 and HiSCR75 ▪ Draining Tunnel Count ▪ IHS4 ▪ DLQI ▪ Skin pain NRS ▪ PK/PD assessments ▪ Other symptom and lesion-based measures per protocol ▪ Adults with moderate-to-severe HS, defined as: – Hurley Stage II/III (up to 40% Stage III allowed) – Total abscess and inflammatory nodule (AN) count ≥5 ▪ Up to 30% of participants may have prior TNF-α inhibitor exposure ▪ Additional eligibility criteria per protocol Randomized, double-blind, placebo-controlled, three-arm study 16-week primary efficacy period followed by a 16-week OLE Tibulizumab dose: 150 mg and 300 mg SC Dose selection informed by Phase 1 PK/PD and target engagement data Efficacy Period (16 weeks) OLE (16 weeks) Study timeline (weeks) 1:1:1 R tibulizumab (n ≈ 75) 150 mg n ≈ 225 placebo (n ≈ 75) participants tibulizumab (n ≈ 75) 300 mg tibulizumab 150 mg 0 2 4 8 12 16 20 24 28 32 Week 32 Final OLE study visit (no SC dose) SC dosing at study visit = Phase 2 study in moderate-to-severe hidradenitis suppurativa |
| ©2026 Zura Bio Ltd. A dual-pathway approach in SSc tibulizumab ZB-106 Anti-BAFF + IL-17 ▪ First and currently only in-class bispecific antibody designed to target BAFF and IL-17 signaling, including IL-17A and IL-17A/F ▪ Phase 2 clinical trial (TibuSURE) ongoing; topline data anticipated in 1H 2027 Tibulizumab is an investigational agent. Its efficacy and safety have not been established or approved by the FDA or any other regulatory agency worldwide. |
| ©2026 Zura Bio Ltd. Systemic sclerosis is a progressive, multisystem autoimmune disease with limited therapeutic options* (*) Two therapies are approved for SSc-ILD; however, no treatment approved for SSc addresses multiple organ systems. Sources: Clarivate/DRG (accessed 19 August 2024); public regulatory disclosures and prescribing information. Acronyms: CGA, Clinical Global Assessment; EU5, five major European markets (France, Germany, Italy, Spain, United Kingdom); FVC, forced vital capacity; HAQ-DI, Health Assessment Questionnaire Disability Index; ILD, interstitial lung disease; mRSS, modified Rodnan Skin Score; PtGA, Patient Global Assessment; SSc, systemic sclerosis; US, United States. 23 Systemic Sclerosis (SSc) is a Rare, Serious Multisystem Autoimmune Disease No therapies are approved that comprehensively address the multisystem pathology of SSc* ~300,000 people are estimated to be living with SSc across major markets (US, EU5, Japan) TibuSURE Phase 2 Trial Evaluates Key Domains of Systemic Sclerosis Other Organs Heart Kidney Liver Stomach SSc-ILD is a major cause of morbidity and mortality in SSc. Two disease-modifying treatments are approved for SSc-ILD Lungs Skin Characterized by Chronic Inflammation and Fibrosis Across Organs Skin fibrosis contributes to functional impairment, disability, and reduced quality of life FVC Forced Vital Capacity mRSS modified Rodnan Skin Score HAQ-DI Health Assessment Questionnaire Disability Index PtGA Patient Global Assessment CGA Clinical Global Assessment Lung Function Skin Fibrosis Functional Impact Patient-Reported Outcome Clinician-Reported Outcome tibulizumab | ZB-106 |
| ©2026 Zura Bio Ltd. A dual-pathway approach in systemic sclerosis 24 Targeting immune drivers of autoimmunity, inflammation, and fibrosis Disease ▪ Severe, progressive, multisystem autoimmune disease ▪ Core features: inflammation, vasculopathy, and fibrosis ▪ No therapies are approved that comprehensively address the multisystem pathology of SSc* Program ▪ Tibulizumab (BAFF + IL-17A bispecific antibody) ▪ Phase 2 TibuSURE clinical study; topline data expected 1H 2027 Biology ▪ Inflammation plays a key role in fibrosis and vasculopathy ▪ Autoreactive B cells and autoantibodies are key inflammatory signature ▪ IL-17 pathway elevation observed in SSc patients Th17 cell IL-17A IL-17A B cell (*) Two therapies are approved for SSc-ILD; however, no treatment approved for SSc addresses multiple organ systems. Acronyms: BAFF, B cell activating factor; IL-17A, interleukin-17A; SSc, systemic sclerosis; Th17, T helper 17 cells. tibulizumab | ZB-106 |
| ©2026 Zura Bio Ltd. IL-17A and BAFF/B cells contribute to inflammation, vasculopathy, and fibrosis in systemic sclerosis Core Disease Features ▪ SSc is characterized by chronic inflammation, vasculopathy, and progressive fibrosis ▪ Infiltration of activated immune cells (macrophages, T cells, B cells) creates a persistent inflammatory tissue environment BAFF / B Cell Biology ▪ BAFF is elevated in SSc and supports survival and activation of autoreactive B cells ▪ Activated B cells produce autoantibodies and inflammatory cytokines (e.g., IL-6) associated with fibrosis and vascular dysfunction IL-17A Biology ▪ IL-17A has been reported to be elevated in subsets of patients with SSc ▪ Preclinical studies suggest IL-17A can activate fibroblasts and endothelial cells, promoting inflammation, immune cell recruitment, and tissue remodeling 25 tibulizumab | ZB-106 Sources: Seki, N. et al. (2024), Cytokine, DOI:10.1016/j.cyto.2024.156534; Ono, Y. et al. (2024), Scientific Reports, DOI:10.1038/s41598-024-76987-6; Lonati, P.A. et al. (2014), PLoS ONE, DOI:10.1371/journal.pone.0105008; Deng, C.-C. et al. (2025), Frontiers in Immunology, DOI:10.3389/fimmu.2024.1522076; Kurasawa, K. et al. (2000), Arthritis & Rheumatism, 43(11), pp. 2455– 2463. doi:10.1002/1529-0131(200011)43:11<2455::aid-anr12>3.0.co;2-k. Acronyms: BAFF, B cell activating factor; IL-6, interleukin-6; IL-17A, interleukin-17A; SSc, systemic sclerosis. |
| ©2026 Zura Bio Ltd. Targeting interconnected immune pathways in systemic sclerosis 26 BAFF- and IL-17–driven inflammation may contribute to vasculopathy and fibrosis, supporting evaluation of multi-pathway therapeutic strategies in SSc ▪ BAFF signaling supports survival of autoreactive B cells ▪ Elevated autoantibody production and cytokine networks (including IL-6, IL-17) are observed in SSc ▪ Immune-mediated endothelial dysfunction contributes to impaired blood flow ▪ Inflammatory cytokines (IL-6, IL-17) thought to promote immune cell infiltration and vascular injury ▪ Fibroblast activation contributes to progressive tissue fibrosis ▪ Excess extracellular matrix deposition (e.g., collagen) is characteristic of SSc INFLAMMATION VASCULOPATHY FIBROTIC REMODELING Sources: Allanore, Y. et al. (2015), Nature Reviews Disease Primers, DOI:10.1038/nrdp.2015.2; Distler, J.H. et al. (2019), Nature Reviews Rheumatology, DOI:10.1038/s41584-019-0322-7; Asano, Y. and Sato, S. (2015), Seminars in Immunopathology, DOI:10.1007/s00281-015-0505-5; Varga, J. and Abraham, D. (2007), Journal of Clinical Investigation, DOI:10.1172/jci31139. Acronyms: BAFF, B cell activating factor; IL-6, interleukin-6; IL-17, interleukin-17; SSc, systemic sclerosis. tibulizumab | ZB-106 |
| ©2026 Zura Bio Ltd. Separately inhibiting IL-17A or BAFF has shown efficacy in placebo-controlled trials for systemic sclerosis Sources: Fukasawa, T. et al. (2022), Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2022-eular.2519; ClinicalTrials.gov ID NCT03957681; Gordon, J.K. et al. (2018), Arthritis & Rheumatology, DOI:10.1002/art.40358; ClinicalTrials.gov ID NCT01670565. Acronyms: BAFF, B cell activating factor; dcSSc, diffuse cutaneous systemic sclerosis; FVC, forced vital capacity; IL-17A, interleukin-17A; IIT, investigator-initiated trial; mRSS, modified Rodnan Skin Score; MMF, mycophenolate mofetil; NS, not significant; QOL, quality of life; SHAQ-DI, Scleroderma Health Assessment Questionnaire–Disability Index; SSc, systemic sclerosis; VAS, visual analog scale. 27 IL-17 RECEPTOR ANTAGONIST – PHASE 3 Brodalumab ▪ Met the primary endpoint of reduced mRSS at Week 24 for skin involvement, and demonstrated improvement in FVC as a secondary endpoint reflecting lung function ▪ Also showed therapeutic effects on lung/respiratory functions, digital ulcers, symptoms of gastroesophageal reflux disease, and QOL without noteworthy safety concerns Δ -21.2 units Δ +5.2% CLINICAL PRECEDENT Phase 3 brodalumab trial (24 weeks) mRSS FVC (% predicted) BAFF ANTAGONIST Belimumab ▪ In a 52-week, investigator-initiated, single-center, double-blind, placebo-controlled pilot trial involving 20 participants with dcSSc on background MMF ▪ Both treatment groups experienced improvements in mRSS, favoring belimumab (-10 vs. -3; p = NS) ▪ Secondary endpoints were met with statistical significance in two endpoints: SHAQ-DI and VAS Raynaud’s phenomenon CLINICAL PRECEDENT Phase 2 belimumab IIT trial (52 weeks) mRSS FVC (% predicted) Δ -7.0 units Δ +7.0% tibulizumab | ZB-106 |
| ©2026 Zura Bio Ltd. 28 (*) Includes secondary and exploratory endpoints Acronyms: CRISS, Combined Response Index in Systemic Sclerosis; FVC, forced vital capacity; HAQ-DI, Health Assessment Questionnaire Disability Index; HRCT, high-resolution computed tomography; ILD, interstitial lung disease; mRSS, modified Rodnan Skin Score; OLE, open-label extension; PK/PD, pharmacokinetics/pharmacodynamics; qHRCT, quantitative high-resolution computed tomography; R, randomization; SC, subcutaneous; SSc, systemic sclerosis. Phase 2 study in diffuse cutaneous systemic sclerosis KEY INCLUSION CRITERIA PLANNED EFFICACY ENDPOINTS PRIMARY ENDPOINT ▪ Change from baseline in mRSS at Week 24 ADDITIONAL ENDPOINTS* ▪ qHRCT lung imaging ▪ FVC ▪ HAQ-DI ▪ revised CRISS (rCRISS) ▪ Adults (18–75 years) with early diffuse cutaneous SSc, enriched for SSc-ILD ▪ Stable background immunosuppressive or antifibrotic therapy ▪ Anti-centromere antibody negative ▪ Disease duration ≤ 7 years ▪ mRSS 15–45 at screening ▪ Additional eligibility criteria per protocol Randomized, double-blind, placebo-controlled design 24-week primary efficacy period, followed by 28-week OLE Tibulizumab dose: 300 mg SC Dose selection informed by Phase 1 PK/PD and target engagement data tibulizumab | ZB-106 n ≈ 80 participants Efficacy Period (24 weeks) Baseline image HRCT 1:1 R tibulizumab (n ≈ 40) 300 mg placebo (n ≈ 40) OLE (28 weeks) tibulizumab 300 mg HRCT HRCT Week 52 (no SC dose) 0 2 4 8 12 16 20 24 28 32 36 40 44 48 52 Study timeline SC dosing (weeks) at study visit = |
| ©2026 Zura Bio Ltd. modified Rodnan Skin Score (mRSS): Endpoint for assessing skin thickness and fibrosis 29 Severe skin thickening and tightening restricts movement and causes painful ulcers on the hands and fingers, significantly impairing daily activities and quality of life. vs Fine Wrinkles (0/3) Severe Thickness (3/3) The mRSS assesses skin thickness in systemic sclerosis patients by evaluating 17 body sites (e.g., face, chest, abdomen, arms, legs). Each site is scored from 0 to 3. The total score ranges from 0 to 51, with higher scores indicating greater skin involvement. 17 Surface Anatomic Areas of the Body 2 Moderate Thickness 1 Mild Thickness 3 Severe Thickness 0 Normal Skin Face Anterior chest Abdomen Upper arm Forearm Hand Fingers Thigh Leg Foot Upper arm Forearm Hand Fingers Thigh Leg Foot with inability to pinch the skin into a fold Sources: Khanna, D. et al. (2017), Journal of Scleroderma and Related Disorders, doi:10.5301/jsrd.5000231; Ferreli, C. et al. (2018), Clinical Reviews in Allergy & Immunology, doi:10.1007/s12016-017-8625-4. tibulizumab | ZB-106 |
| ©2026 Zura Bio Ltd. In phase 2, lung involvement using qHRCT is a key secondary endpoint 30 Sources: Goldin, J. et al. (2018), Annals of the American Thoracic Society, doi:10.1513/annalsats.201802-079OC; Zura Bio internal planning. Acronyms: ILD, interstitial lung disease; MMF, mycophenolate mofetil; qHRCT, quantitative high-resolution computed tomography; QILD, quantitative interstitial lung disease; QLF, quantitative lung fibrosis; SSc, systemic sclerosis. ILD includes various pulmonary disorders marked by inflammation and progressive lung fibrosis, resulting in restrictive lung function and impaired gas exchange. SSc often leads to ILD due to immune system dysregulation and subsequent lung interstitial fibrosis. vs Healthy Lung Fibrotic Lung QILD by HRCT provides a sensitive measure of lung involvement, detecting changes as small as 2%. Example of improvement after 24 months of MMF in total lung involvement The blue and red areas show QLF, while the yellow area shows quantitative ground glass. The entire colored area represents QILD. After 24 months, QLF areas decreased (arrow in B). tibulizumab | ZB-106 |
| ©2026 Zura Bio Ltd. Key takeaways Clear differentiation Tibulizumab is the first and currently only in-class bispecific antibody designed to simultaneously target BAFF and IL-17– mediated signaling, addressing immune complexity beyond single-pathway approaches 31 Acronyms: BAFF, B cell activating factor; IL-17, interleukin-17. Defined, anticipated near-term clinical catalysts Two independent Phase 2 trials (TibuSHIELD and TibuSURE) evaluating a dual-pathway strategy in diseases with significant unmet need and potential multi-billion dollar market opportunities Platform optionality Multi-pathway immune biology provides potential for expansion into additional autoimmune indications, subject to clinical validation Nasdaq: ZURA |
